FAST NEWS: Antengene’s loss widens on lower forex income, rising R&D costs
The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) reported last Friday its net loss for the first half of 2023 widened 51.5% year-on-year to 144 million yuan ($19.8 million). Looking up: The…
FAST NEWS: Antengene appoints Hansoh to commercialize myeloma drug
The latest: Antengene Corporation Ltd. (6996.HK) announced Friday it has entered into an exclusive collaboration agreement with Hansoh Pharmaceutical Group Co. Ltd. (3692.HK) for the commercialization of the relapse or…
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
- Innogen Pharma jostles for a slice of the weight-loss market
- PegBio aims to bulk up its finances to deliver weight-loss drugs
